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BACKGROUND AND PURPOSE
Kinase inhibitors are a common treatment for cancer. Class I kinase inhibitors that target the ATP-binding pocket are particularly
prevalent. Many of these compounds are cardiotoxic and can cause arrhythmias. Spontaneous release of Ca2+ via cardiac
ryanodine receptors (RyR2), through a process termed store overload-induced Ca2+ release (SOICR), is a common mechanism
underlying arrhythmia. We explored whether class I kinase inhibitors could modify the activity of RyR2 and trigger SOICR to
determine if this contributes to the cardiotoxic nature of these compounds.
EXPERIMENTAL APPROACH
The impact of class I and II kinase inhibitors on SOICR was studied in HEK293 cells and ventricular myocytes using single-cell Ca2+
imaging. A specific effect on RyR2 was confirmed using single channel recordings. Ventricular myocytes were also used to de-
termine if drug-induced changes in SOICR could be reversed using anti-SOICR agents.
KEY RESULTS
Class I kinase inhibitors increased the propensity of SOICR. Single channel recording showed that this was due to a specific effect
on RyR2. Class II kinase inhibitors decreased the activity of RyR2 at the single channel level but had little effect on SOICR. The
promotion of SOICR mediated by class I kinase inhibitors could be reversed using the anti-SOICR agent VK-II-86.
CONCLUSIONS AND IMPLICATIONS
Part of the cardiotoxicity of class I kinase inhibitors can be assigned to their effect on RyR2 and increase in SOICR. Compounds with
anti-SOICR activity may represent an improved treatment option for patients.
Abbreviations
AM, acetoxymethyl ester; Cmax, peak plasma concentration; FSOICR, release threshold for SOICR; FTermi, termination
threshold for SOICR; KRH, Krebs–Ringer HEPES; Po, channel open probability; RyR2, cardiac ryanodine receptors type 2;
SOICR, store overload-induced calcium release; SR, sarcoplasmic reticulum; Tc, channel closed time; TES,
tris[hydroxymethyl]methyl-2-aminoethanesulfonic acid; To, channel open time
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Introduction
Over the past decades, there has been a progressive develop-
ment of new drugs to treat cancer. Leading the way are small
compounds designed to inhibit protein kinases involved in
metabolism, cell survival and cell cycle progression. There
are around 500 protein kinases present in the human
kinome, and around 150 of them have been linked to the
progression of various diseases including inflammatory
diseases, cardiovascular diseases, metabolic diseases and
cancer (Cohen, 2001; Wilson et al., 2018). Several strategies
are employed to inhibit kinases pharmacologically, the most
common being those that target the active conformation of
the ATP-binding pocket; compounds termed class I kinase
inhibitors. These compounds mimic the hydrogen bonds
that normally form between ATP and the kinase. Given the
conservation of this interaction of ATP and kinase amongst
a range of kinases, these drugs are often relatively non-
selective for a specific kinase (Liu and Gray, 2006; Klaeger
et al., 2017). A second class of inhibitors with potentially
greater specificity are termed class II kinase inhibitors, which
inhibit the kinase by interacting with the inactive form of the
kinase. These compounds bind adjacently to the ATP-binding
pocket and modify it to prevent activation (Liu and Gray,
2006; Hu et al., 2015).
Although great advances have been made in treating
cancer, an ongoing problem remains the off-target toxicity
of these compounds. An organ frequently adversely
affected by these drugs is the heart, where several anti-cancer
compounds (both class I and class II) have been linked to
electrical disturbances (Schmidinger et al., 2008; Shah and
Morganroth, 2015). A common mechanism leading to
electrical disturbances and arrhythmias is the disruption of
intracellular Ca2+ release within individual cardiomyocytes
(Bai et al., 2013). Under normal conditions, the controlled
release of Ca2+ from the intracellular Ca2+ store [sarcoplasmic
reticulum (SR)] through the cardiac ryanodine receptor
(RyR2) provides the bulk of the Ca2+ required for contraction
(Bers, 2002). However, the uncontrolled release of Ca2+
through RyR2 is pathogenic and linked to both arrhythmias
and cardiomyopathies. A unifying mechanism underlying
RyR2 dysfunction is store overload-induced Ca2+ release
(SOICR) (Liu et al., 2013), otherwise known as spontaneous
Ca2+ release. We and others have shown that SOICR can be trig-
gered due to an increase in SRCa2+ content or due to an increase
in the sensitivity of RyR2 to activation by SR Ca2+ (Kashimura
et al., 2010; Zhang et al., 2014; Zhang et al., 2015). Pertinently,
we have previously shown that the drug-induced activation of
RyR2 partially underlies the cardiotoxicity of anthracyclines, a
different class of chemotherapeutic drugs (Hanna et al., 2014).
Combined, this led us to hypothesize that part of the
cardiotoxicity of class I and II kinase inhibitors is due to an in-
crease in RyR2 activity and SOICR.
In this study, we examined the effect of two class I and two
class II kinase inhibitors on the activity of RyR2 and SOICR.
The class I inhibitors studied were CX-4545 (silmitasertib)
and sunitinib (sutent), inhibitors of protein kinase CK2
and cyclin-dependent kinase 2 respectively (Mendel
et al., 2003; Ferguson et al., 2011). The class II inhibitors
examined were ponatinib (ICLUSIG) and nilotinib
(Tasigna), both multi-targeted kinase inhibitors with a
primary target of BCR-ABL TK (O’Hare et al., 2009). We
found that both class I kinase inhibitors increased the
incidence of SOICR by sensitizing RyR2 to activation by
luminal Ca2+. However, neither class II kinase inhibitor en-
hanced RyR2 channel activity or the incidence of SOICR.
These data suggest that part of the cardiotoxicity of class
I kinase inhibitors can be attributed to a specific effect on
RyR2, leading to an increase in SOICR, a precursor of ar-
rhythmia and cardiomyopathies. Thus, this study identifies
a novel mechanism that could underlie the cardiotoxicity
of class I kinase inhibitors.
Methods
Single-cell Ca2+ imaging (cytosolic Ca2+)
Measurements of cytosolic Ca2+ were conducted in stable,
inducible HEK293 cells (RRID:CVCL_U427) expressing
RyR2, generated as previously described (Waddell et al.,
2016). RyR2 expression was induced ~16–18 h before the ex-
periment via the addition of tetracycline (0.1 μg·mL1). In or-
der to visualize Ca2+ transients, cells were loaded with 2 μMof
the acetoxymethyl ester (AM) form of the Ca2+ indicator,
fluo-4 (Life Technologies) in 0 Ca2+ Krebs–Ringer HEPES
(KRH) buffer containing (mM): 125 NaCl, 5 KCl, 25 HEPES,
6 glucose, and 1.2 MgCl2 (pH 7.4) and BSA (1 mg·mL
1) for
10 min at room temperature. Cells were then incubated in
the same solution plus each kinase inhibitor or DMSO as a
vehicle control, for 10 min, in the absence of fluo-4 to allow
de-esterification to take place. The cells were then mounted
on an epi-fluorescence microscope (Nikon Eclipse Ti, 20×
plan-fluor objective) and continuously superfused with KRH
solution containing various concentrations of CaCl2
(0.1–1.0 mM) along with each kinase inhibitor or DMSO at
room temperature. At the end of the experiments, 20 mM
caffeine was applied to deplete the intracellular Ca2+ store.
Fluo-4 AM dye was excited at 470 nm (40 nm bandwidth)
every 2 s with an exposure time of 100 ms using a CoolLED
system (Coherent Scientific Pty. Ltd, Australia). Fluorescence
of fluo-4 was detected through a long-pass dichroic mirror
(495 nm) and a long-pass emission filter (515 nm) by a Zyla
4.2 Plus sCMOS camera (Coherent Scientific Pty. Ltd). The cy-
tosolic Ca2+ fluorescence is represented by F/F0, where F is the
Ca2+ fluorescence intensity at any time and F0 is the average
fluorescence intensity recorded in 0 Ca2+ KRH solution.
Normalization to F0 was performed to control for variations
in the amount of fluo-4 loaded into each cell. The percentage
of cells experiencing SOICR at each external Ca2+ concentra-
tion ([Ca2+]o) was determined using a custom image
analysis script written in the Python programming language
(code available on request). Measurements were carried out
at 21 ± 2°C.
Single-cell Ca2+ imaging (luminal Ca2+)
Stable, inducible HEK293 cells expressing RyR2 as described
above were used with the additional transfection of 2 μg
cDNA encoding for D1ER. D1ER transfection took place
24 h before RyR2 induction. The cells were incubated with
each inhibitor (or DMSO) for 10 min before each experiment.
The cells were then mounted on an epi-fluorescence
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microscope (Nikon Eclipse Ti, 20× plan-fluor objective, Co-
herent Scientific Pty. Ltd) and continuously superfused at
room temperature with KRH containing various concentra-
tions of Ca2+ (1 and 2 mM), tetracaine (2 mM to block
RyR2) and caffeine (20 mM to deplete the SR store) along
with either DMSO or kinase inhibitor. Fluorescent images
of HEK293 cells were acquired every 2 s with an exposure
time of 100 ms and excitation at 436 nm (20 nm band-
width). The emissions of YFP and CFP were captured with
the addition of a beamsplitter at 535 nm (40 nm band-
width) and 480 nm (30 nm bandwidth) respectively. Two
images were collected by a CoolSNAP HQ2 CCD camera
(Photometrics, AZ, USA) using a dual-channel imaging
system (DV2). The amount of FRET was determined from
the ratio of the emissions at 535 and 480 nm (YFP : CFP)
as previously described (Waddell et al., 2016; Zhang et al.,
2016). From each trace, several parameters were deter-
mined. The mean maximum ratio in the presence of tetra-
caine represents the maximum store level (Fmax), while the
mean minimum ratio in the presence of caffeine represents
a fully depleted store (Fmin). These values were calculated as
the largest or smallest mean over a rolling 30 s period
during the plateau phase of tetracaine and caffeine treat-
ment. From this, the store size was calculated (Fmax  Fmin).
The release threshold for SOICR (FSOICR) expressed as a per-
centage of store size was calculated from the mean of each
of the maximum values before each of the final three
SOICR events. Similarly, the termination of SOICR (FTermi),
also expressed as percentage of store size, was calculated
from the mean of each of the minimum points in the final
three nadirs before application of tetracaine. Measurements
were carried out at 21 ± 2°C.
Isolation and single-cell imaging of rat
ventricular myocytes
Individual myocytes were isolated by enzymatic digestion
from 2- to 3-month-old specific pathogen-free male
Sprague–Dawley rats (RRID:MGI:5651135) as previously
described (Xiao et al., 2007). The isolated cardiomyocytes
were loaded with 2 μM fluo-4 for 10 min in KRH containing
1 mM Ca2+. The cells were then mounted on an epi-
fluorescence microscope (Nikon Eclipse Ti, 20× plan-fluor ob-
jective, Coherent Scientific Pty. Ltd) and continuously
superfused at room temperature with KRH containing 1 mM
Ca2+, 1 mM Ca2+ + DMSO or 10 μM of CX-4945, ponatinib
or nilotinib, or 1 μM sunitinib. Caffeine (20 mM) was applied
at the end of each experiment to deplete the SR store and con-
firm cell viability. Cells were paced at 0.5 Hz apart from a
2 min window during which the number of spontaneous
Ca2+ waves was counted. In those experiments examining
the effect of VK-II-86, cells were pre-incubated in 1 μM VK-
II-86 for 30 min prior to the experiment. Fluo-4 AM dye was
excited at 470 nm (40 nm bandwidth) every 100 ms with an
exposure time of 50 ms using a CoolLED system (Coherent
Scientific Pty. Ltd). Fluorescence of fluo-4 was detected
through a long-pass dichroic mirror (495 nm) and a long-pass
emission filter (515 nm) by an Andor Zyla 4.2 Plus sCMOS
camera (Coherent Scientific Pty. Ltd). Measurements were
carried out at 21 ± 2°C.
Single channel recordings
Sheep cardiac SR vesicles were incorporated into lipid bilayers
in solutions containing (mM) cis: 230 CsCH3O3S, 20 CsCl, 1
CaCl2 and 10 N-tris[hydroxymethyl]methyl-2-aminoethane-
sulfonic acid (TES; pH 7.4) and trans: 30 Cs CsCH3O3S, 20
CsCl, 1 CaCl2 and 10 TES (pH 7.4) as described previously
(Beard et al., 2002; Richardson et al., 2017). Following SR ves-
icle incorporation, cis (cytoplasmic) Ca2+ was adjusted to
1 μM with BAPTA using a Ca2+ electrode. Trans [CsCH3O3S]
was increased to 230 mM, while trans [Ca2+] was 1 mM
throughout. Data were filtered at 1 kHz and sampled at
5 kHz. All electrical potentials are expressed as that of cyto-
plasmic solution relative to the luminal solution. Single
channel recordings were obtained at +40 and 40 mV. These
voltages were chosen to ensure a large current flow through
the channel, which would maximize the signal-to-noise ra-
tio, without easily breaking the bilayer. Single channel pa-
rameters from 30 s of recording were obtained using the
Channel3 software (N.W. Laver, nic@niclaver.com; based on
the original Channel2 software developed by P.W. Gage and
M. Smith, John Curtin School of Medical Research, Canberra,
Australia). The threshold levels for channel opening were set
to exclude baseline noise at ∼20% of the maximum single
channel conductance and open probability (Po), mean open
time (To) and mean closed time (Tc) measured (Copello
et al., 1997; Marengo et al., 1998; Smith et al., 2013). Currents
at both positive and negative potentials were monitored to
assess possible voltage-dependent effects of the peptide. As
no voltage-dependent effects were observed, independent pa-
rameters measured at +40 and40mVwere averaged for each
channel. Control activity with 1 μM cytoplasmic Ca2+ was re-
corded for 3 to 5 min at the start of each experiment. Then, in
the first series of experiments, 10 μM CX-4945, ponatinib or
nilotinib or 1 μM sunitinib were added to the cytoplasmic
side of the channel (cis solution), and channel activity was
recorded for 5 to 10 min. In a second series of experiments,
2 mM Na2ATP was added to the cis solution and channel
activity recorded for 3 to 5 min before adding CX-4945 or
sunitinib. Measurements were carried out at 21 ± 2°C.
Experiments involving animals
Animal studies are reported in compliance with the AR-
RIVE guidelines (Kilkenny et al., 2010). All experiments
were approved (#DET29/16) and conducted within the
guidelines of the Animal Ethics Committee of the Univer-
sity of Otago, New Zealand, and adhered to the New
Zealand Animal Welfare Act 1999, which complies with
the US National Institutes of Health Guide for the Care
and Use of Laboratory Animals. This study used 2- to
3-month-old (~250 g) specific pathogen-free male
Sprague–Dawley rats, a strain and age commonly used for
myocyte isolation, for example see study of Xiao et al.
(2007). All animals were housed at least two animals per
cage using standard conditions including filter topped cage
with cage enrichment. All animals were killed using a le-
thal dose of pentobarbital (100 mg·kg1).
Randomization, blinding and normalization
In all experiments, the order of drug treatments was random-
ized each day. All experiments were collected by one operator
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and analysed by a second using anonymized file names.
Moreover, where possible, the analysis was automated
preventing operator bias. Where possible, we have provided
and analysed absolute values. Normalization was only
applied to the myocyte and the supplementary Western
blotting data. For myocytes, this was to control for unwanted
differences in basal cell activity between animals. For
Western blotting, the protein band density can vary dramat-
ically between blots, so normalization was applied to remove
unwanted sources of variation. For single channels, while
statistical analysis was performed on absolute Po, the relative
Po of some experiments is also reported in the text for easy
comparison between treatments.
Unequal group sizes
The group size n was not equal in all experiments. For the
HEK293 cell experiments, the data were analysed based on
experimental number, but each experiment was an average
of a large number of cells. Rather than setting an experi-
mental n, we use the total number of cells to determine
our group size. Cell density varies, so to provide the same
number of cells requires a different number of experi-
ments (leading to a variation in n). Additionally, for the
HEK293 cell experiments, we performed at least two con-
trol experiments every day to ensure consistency of cells
between days. For each drug examined, we also perform
at least two experiments under that condition per day. It
is not possible to test all drug conditions on each day;
therefore, the n for controls is typically larger than any
drug condition; this is particularly true where a large range
of drug concentrations was studied. For single channel
recordings, some channels did not provide stable record-
ings and were not included leading to a small variation
in n. There is also a small difference in n for the
myocyte-based studies. This is due to the randomization
of drug treatments across myocytes isolated from different
animals and because some myocyte isolations produce
fewer usable cells. This precluded the testing of all drugs
in all animals.
Data and statistical analysis
The data and statistical analysis comply with the recommen-
dations on experimental design and analysis in pharmacol-
ogy (Curtis et al., 2018).
Results are presented as mean ± SEM. For statistical analy-
sis of Figures 1 and 2, a two-way ANOVAwith a Dunnett’s post
hoc test was performed. For Figures 3, 4 and 7, a non-
parametric ANOVA (Kruskal–Wallis) with Dunn’s post hoc test
was performed. Absolute differences in channel properties
(Figures 5 and 6 and Supporting Information Figure S4) were
compared using a paired Student’s t-tests or paired ANOVA
with a Tukey post hoc test. Normal distribution for parametric
analysis was determined using a Shapiro–Wilk normality test.
Post hoc tests were only performed if F was significant. All
Figure 1
Class I kinase inhibitors increase the propensity for SOICR. HEK293 cells stably expressing RyR2 were loaded with fluo-4 in KRH buffer. Cells were
superfused with KRH containing 0, 0.1, 0.2, 0.3, 0.5 or 1 mM Ca2+. At the end of each experiment, cells were perfused with 20 mM caffeine.
Representative fluo-4 traces presented from cells treated with (A) 1, 3 or 10 μM CX-4945 or (C) 1, 3 or 5 μM sunitinib. The fraction of cells
experiencing SOICR at each [Ca2+]o when treated with each concentration of CX-4945 or sunitinib (B and D respectively). Data shown are
mean ± SEM. For CX-4945, n = 25 (vehicle), 6 (1 μM), 5 (3 μM) or 8 (10 μM) independent experiments. For sunitinib, n = 6 (vehicle), 5
(1 μM), 5 (3 μM) or 6 (5 μM) independent experiments.
A D Chakraborty et al.
776 British Journal of Pharmacology (2019) 176 773–786
significance was determined as P < 0.05 (denoted by * or # in
figures). All data analysis and data plotting were performed
using GraphPad Prism 7 (RRID:SCR_002798).
Drugs, chemicals and reagents
NaCl, KCl, HEPES, glucose, MgCl2, CaCl2, caffeine, tetra-
caine, tetracycline, DMSO, CsCH3O3S, CsCl, TES, BAPTA,
Na2ATP and BSA were obtained from Sigma-Aldrich (Castle
Hill, NSW, Australia). Fluo-4 AM was obtained from
ThermoFisher (Waltham, MA, USA). VK-II-86 was synthe-
sized at the University of Otago according to the methods de-
scribed by Zhou et al. (2011). CX-4945 was obtained from
Assay Matrix (Ivanhoe North, Australia), ponatinib and suni-
tinib from LC Laboratories (Woburn, MA, USA) and nilotinib
from Santa Cruz Biotechnology (Dallas, TX, USA).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org,
the common portal for data from the IUPHAR/BPS Guide to
PHARMACOLOGY (Harding et al., 2018), and are permanently
archived in the Concise Guide to PHARMACOLOGY 2017/18
(Alexander et al., 2017a,b).
Results
Class I kinase inhibitors increase the propensity
for SOICR
HEK293 cells expressing RyR2 have been well established to
display SOICRwith very similar characteristics to cardiac cells
(Zhang et al., 2014; Waddell et al., 2016). In this study,
HEK293 cells expressing RyR2 were used to investigate the
impact of class I and II kinase inhibitors on the occurrence
of SOICR. To assess the impact of the kinase inhibitors on
SOICR, HEK293 cells were loaded with the Ca2+ indicator
fluo-4 AM and continuously superfused with KRH at room
temperature. SOICR was induced by increasing the [Ca2+]o,
and the occurrence of SOICR was monitored using single-cell
imaging. Figure 1A shows representative traces from cells
treated with vehicle (DMSO), 1, 3 or 10 μM CX-4945. Under
all conditions, the cells experienced Ca2+ oscillations as the
[Ca2+]o increased. As shown, cells treated with CX-4945 typi-
cally experienced SOICR at lower [Ca2+]o than cells treated
with vehicle. To quantify this, the cumulative fraction of
caffeine-responsive cells experiencing SOICR at each [Ca2+]o
was determined at each CX-4945 concentration. Figure 1B
depicts the propensity of SOICR (mean ± SEM) in cells treated
with vehicle, 1, 3 or 10 μM CX-4945. Vehicle-treated cells
typically experienced no oscillations at lower [Ca2+]o.
Figure 2
Class II kinase inhibitors do not affect the propensity for SOICR. HEK293 cells stably expressing RyR2 were loaded with fluo-4 in KRH buffer. Cells
were superfused with KRH containing 0, 0.1, 0.2, 0.3, 0.5 or 1 mM Ca2+. At the end of each experiment, cells were perfused with 20 mM caffeine.
Representative fluo-4 traces presented from cells treated with 1, 3 or 10 μM ponatinib (A) or nilotinib (C). (B) The fraction of cells experiencing
SOICR at each [Ca2+]o when treated with vehicle, 1, 3 or 10 μM ponatinib. (D) The fraction of cells experiencing SOICR at each [Ca
2+]o
when treated with vehicle, 1, 3 or 10 μM nilotinib. Data shown are mean ± SEM. For ponatinib, n = 16 (vehicle), 8 (1 μM), 9 (3 μM) or 12
(10 μM) independent experiments. For nilotinib, n = 16 (vehicle), 12 (1 μM), 8 (3 μM) or 10 (10 μM) independent experiments.
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However, CX-4945-treated cells experienced SOICR at these
lower [Ca2+]o. For example, at 0.2 mM [Ca
2+]o, 61 ± 10% of
cells treated with 10 μM CX-4945 experienced SOICR
compared to 17 ± 3% vehicle-treated cells. Similarly, a
significantly larger fraction of cells experienced SOICR at
0.3 mM [Ca2+]o, 1 μM (50 ± 5%), 3 μM (50 ± 7%) or 10 μM
(73 ± 8%) CX-4945 compared to vehicle (35 ± 3%).
Comparable to the effect of CX-4945, sunitinib dramati-
cally increased the fraction of cells experiencing SOICR at
very low [Ca2+]o. Figure 1C shows representative traces of
cells treated with vehicle, 1, 3 or 5 μM sunitinib. Data from
HEK293 cells treated with 10 μM are not included as
treatment with concentrations of sunitinib >5 μM led to a
marked increase in basal Ca2+ and a loss of a caffeine response
(loss of cell viability). Cells treated with sunitinib start to
oscillate from 0.1 mM [Ca2+]o, whereas the majority of
vehicle-treated cells do not start to experience SOICR until
0.3 mM [Ca2+]o. Figure 1D depicts the propensity for SOICR
under each condition. At 0.2 mM [Ca2+]o, 31 ± 11%,
34 ± 6% and 40 ± 6% of cells experienced SOICR when treated
with 1, 3 or 5 μM sunitinib respectively. Only 6 ± 2% of
vehicle-treated cells experienced SOICR at the same [Ca2+]o.
Likewise, at 0.3 mM [Ca2+]o, sunitinib markedly increased
the % of cells experiencing SOICR [1 μM (48 ± 7%), 3 μM
Figure 3
Class I kinase inhibitors reduce the release threshold for SOICR. HEK293 cells stably expressing RyR2 were transfected with the luminally expressed
FRET-based Ca2+ indicator, D1ER. The cells were superfused with KRH containing 1 or 2 mM Ca2+ with or without 10 μM CX-4945 or 1 μM
sunitinib. At the end of each experiment, cells were perfused with 2mM tetracaine and 20mM caffeine to determine the maximum andminimum
store capacities respectively. (A) Representative traces from HEK293 cells treated with vehicle, 10 μM CX-4945 or 1 μM sunitinib. Dashed lines
represent the release threshold (FSOICR), termination threshold (FTermi) and maximum (Fmax) and minimum (Fmin) store capacities. Mean ± SEM
values of FSOICR, FTermi and store size are shown in panels (B) to (D) and were calculated using the equations shown in the top trace of panel
(A). n = 14, 15 and 9 independent experiments for vehicle, CX-4945 and sunitinib respectively. *P < 0.05 versus vehicle
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(57 ± 4%), 5 μM (64 ± 3%) vs. vehicle (19 ± 4%)]. Using these
values, we calculated the EC50 for each drug. At physiological
(1 mM) [Ca2+]o, the EC50 for CX-4945 is 2.4 μM and is 0.8 μM
for sunitinib (Supporting Information Figure S1).
Class II kinase inhibitors do not alter the
propensity for SOICR
Wenext explored whether class II kinase inhibitors could also
increase SOICR. Given class II inhibitors bind adjacent to the
inactive ATP-binding pocket of kinases, they likely have a
different effect on RyR2. Figure 2A shows representative
traces of HEK293 cells treated with vehicle, 1, 3 or 10 μM of
the class II kinase inhibitor ponatinib. Figure 2A,B shows
that, unlike class I kinase inhibitors, cells treated with
ponatinib experience a similar propensity for SOICR as the
vehicle control at all [Ca2+]o. To explore whether the lack of
effect on SOICR was specific to ponatinib, we also tested a
second class II kinase inhibitor, nilotinib. Consistent with
ponatinib, 1, 3 nor 10 μM nilotinib impacted the propensity
for SOICR at any [Ca2+]o (Figure 2C,D).
Class I but not class II kinase inhibitors
decrease the release threshold for SOICR
Our previous work studying the effect of caffeine and
oxidation has shown that a common mechanism by which
the propensity of SOICR is increased is due to a reduction in
Figure 4
Effect of class II kinase inhibitors on SOICR dynamics. HEK293 cells stably expressing RyR2 were transfected with the luminally expressed FRET-
based Ca2+ indicator, D1ER. The cells were superfused with KRH containing 1 or 2 mM Ca2+ with or without 10 μM ponatinib or nilotinib. At
the end of each experiment, cells were perfused with 2 mM tetracaine and 20 mM caffeine to determine the maximum and minimum store ca-
pacities respectively. (A) Representative traces from HEK293 cells treated with vehicle, 10 μM ponatinib or nilotinib. Dashed lines represent the
release threshold (FSOICR), termination threshold (FTermi) and maximum (Fmax) and minimum (Fmin) store capacities. Mean ± SEM values of FSOICR,
FTermi and store size are shown in panels (B) to (D) and were calculated using the equations shown in the top trace of panel A. n = 11, 8 and 7
independent experiments for vehicle, ponatinib and nilotinib respectively.
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Figure 5
Effect of class I and II kinase on the activity of RyR2 single channels. (A) Representative 3 s continuous segments of channel currents recorded at
+40 mV. The first column shows recordings before the application of each kinase inhibitor, and the second column shows the same channel fol-
lowing the application of each kinase inhibitor (10 μM CX-4945, ponatinib, nilotinib or 1 μM sunitinib) to the cytosolic side of the channel. Po
values shown were calculated over a full 30 s recording. (B) Po (mean ± SEM) for channels before and after the addition of each kinase inhibitor.
n = 6, 6, 5 and 5 independent channels/experiments for CX-4945, sunitinib, ponatinib and nilotinib respectively.
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the FSOICR (Kong et al., 2008; Waddell et al., 2016). Therefore,
we next explored the effect of class I and class II kinase inhib-
itors on FSOICR (which is expressed as a percentage of the total
store) using the luminally expressed Ca2+ sensor D1ER as
previously described (Jones et al., 2008; Zhang et al., 2016).
We also examined the termination threshold (the intracellu-
lar Ca2+ store level, expressed as a percentage of the total
store), at which SOICR events terminate (FTermi), controlled
by the inactivation of RyR2 due to partial depletion of SR
Ca2+ (Zima et al., 2008; Tang et al., 2012) or luminal Ca2+-de-
pendent deactivation of RyR2 (Lukyanenko et al., 1998).
Figure 3A shows representative D1ER traces recorded from
HEK293 cells expressing RyR2 treated with vehicle, 10 μM
CX-4945 or 1 μM sunitinib. FSOICR was determined by the
mean FRET ratio immediately prior to each SOICR event
(downward deflection), FTermi was determined by the mean
FRET ratio of the nadir of SOICR and the maximum store
was determined in the presence of 2 mM tetracaine (Fmax)
and the minimum store in the presence of 20 mM caffeine
(Fmin). Figure 3B–D shows the mean ± SEM for FSOICR, FTermi
and store size in cells treated with vehicle, 10 μM CX-4945
or 1 μM sunitinib. The presence of CX-4945 significantly re-
duced both FSOICR (CX-4945 81.0 ± 1.8, vehicle 91.5 ± 0.8)
and FTermi (CX-4945 47.7 ± 1.6, vehicle 53.4 ± 1.3) without
altering the total Ca2+ store size. A similar effect on FSOICR
was seen in cells treated with sunitinib (sunitinib
86.8 ± 2.881, vehicle 91.5 ± 0.8); however, sunitinib did not
result in a significant reduction in FTermi (sunitinib
51.0 ± 1.0, vehicle 53.4 ± 1.3). In contrast to the class I kinase
inhibitors, neither ponatinib nor nilotinib had any effect on
FSOICR or FTermi (Figure 4A–C). Consistent with the class I
kinase inhibitors, neither class II inhibitor had any effect on
the total Ca2+ store size (Figure 4D).
Class I and II kinase inhibitors regulate RyR2 at
the single channel level
We next explored whether the change in SOICR could be due
to changes in the phosphorylation state of RyR2 as RyR2
phosphorylation of RyR2 at S2808 and S2814 has been
previously shown to increase RyR2 activity (Xiao et al.,
2007; Dobrev and Wehrens, 2014). Phosphorylation of
RyR2 at S2808 and S2814 was determined in lysates prepared
from HEK293 cells treated with each kinase inhibitor using
specific phospho-antibodies to each site. Supporting Infor-
mation Figure S2 shows that the phosphorylation state of
Figure 6
Synergistic effect of ATP and class I kinase inhibitors. (A and B) Representative 3 s continuous segments of channel currents recorded at +40 mV.
The first row shows recordings before the application of ATP, the second row the same channel following the application of 2 mM ATP and the
third row after the application of either 10 μM CX-4945 (A) or 1 μM sunitinib (C). (B and D) Po (mean ± SEM) for channels before and after
treatment with ATP and ATP plus each kinase inhibitor. n = 8 and 6 independent channels/experiments for CX-4945 and sunitinib respectively.
*P< 0.05 versus control, # P< 0.05 versus ATP.
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RyR2 remained unchanged when treated with any of the
kinase inhibitors.
In the absence of change in the phosphorylation state of
RyR2, we then determined if the change in FSOICR could be
attributed to a specific effect of the drugs on single RyR2
channels. Single channel currents were recorded in RyR2
channels incorporated into artificial lipid bilayers from
RyR2-enriched cardiac SR vesicles. Figure 5A shows represen-
tative recordings of channels before and after the addition of
10 μM CX-4945, ponatinib and nilotinib and 1 μM sunitinib
to the cytoplasmic side of the channel. As shown in Figure 5B,
the addition of CX-4945 resulted in a significant increase in
the open probability (Po) (0.02 ± 0.006 and 0.05 ± 0.01 for
vehicle and CX-4945-treated channels respectively) and
corresponding decrease in the open time (To) (Supporting
Information Figure S3). The increase in Po caused by CX-
4945 at this fixed luminal [Ca2+] likely underlies the decrease
in FSOICR and corresponding increase in SOICR propensity
observed in the previous experiments. Surprisingly, unlike
CX-4945, and in contrast to its effect on SOICR, sunitinib
led to a decrease in Po (from vehicle: 0.01 ± 0.004 to sunitinib:
0.004 ± 0.003), which could be attributed to an increase in Tc
(Supporting Information Figure S3). The addition of both
class II kinase inhibitors also led to a significant decrease in
the Po (ponatinib: from 0.03 ± 0.008 to 0.009 ± 0.003;
nilotinib: from 0.01 ± 0.003 to 0.006 ± 0.002).
Class I inhibitors increase RyR2 channel
activity in the presence of ATP
In the previous set of experiments, 1 μM sunitinib unexpect-
edly inhibited RyR2 which is inconsistent with the increase
in SOICR previously observed (Figures 1 and 3). It is well
established that effective activation of RyR2 requires the
presence of ATP which works synergistically with Ca2+ (Yang
and Steele, 2000; Lindsay et al., 2018). Therefore, we next
examined the effect of CX-4945 and sunitinib in the presence
of 2 mM ATP (Na2ATP), a concentration sufficient to elicit a
maximal and physiological activation of RyR2 (Yang and
Steele, 2000; Tencerová et al., 2012). As can be seen in
Figure 6, the addition of ATP alone resulted in a modest
increase in the Po of RyR2 (for To and Tc, see Supporting
Information Figure S3). The addition of CX-4945 further in-
creased the Po of RyR2 (Figure 6B; pre-ATP: 0.022 ± 0.005;
+ATP: 0.063 ± 0.02; +CX-4945: 0.105 ± 0.015). This suggests
that CX-4945 can increase RyR2 activity in the presence and
absence of ATP but is more potent when combined with
ATP (increase in relative Po in the absence of ATP was
2.16 ± 0.67 vs. 4.82 ± 0.7 when added in the presence of
ATP). Interestingly, and in stark contrast to the effect
observed in the absence of ATP, sunitinib dramatically in-
creased the Po when added in the presence of ATP (Figure 6C;
pre-ATP: 0.01 ± 0.002; +ATP: 0.09 ± 0.03; +sunitinib:
0.24 ± 0.05). This is consistent with the increase in SOICR
observed at the cell level suggesting that the effect of
sunitinib is strongly ATP dependent. Although CX-4945
and sunitinib behave differently in the absence of ATP, in
the presence of ATP, both result in a comparable increase in
relative Po (1.67 ± 0.69 and 2.63 ± 0.52 for CX-4945 and
sunitinib respectively). This is in keeping with the analogous
increase in SOICR mediated by both drugs.
Class I kinase inhibitors but not class II kinase
inhibitors increase the propensity for
spontaneous Ca2+ waves in ventricular
myocytes
Although HEK293 cells stably expressing RyR2 and single
channel recordings provide excellent models to interrogate
SOICR dynamics and specific effects on RyR2 function,
they lack some of the regulatory proteins required for
RyR2 function in situ. To determine the impact of class I
and II kinase inhibitors on RyR2 in situ, the propensity
for SOICR (Ca2+ waves) was measured in freshly isolated
rat ventricular myocytes. Ventricular myocytes were loaded
with the Ca2+ indicator fluo-4 and paced at 0.5 Hz. Cells
were superfused with KRH containing 1 mM [Ca2+]o and
10 μM CX-4945, ponatinib and nilotinib and 1 μM suniti-
nib or vehicle control. After 10 min, pacing was stopped
and the frequency of spontaneous Ca2+ waves determined
over 2 min. Figure 7A shows the number of Ca2+ waves
per minute following the cessation pacing normalized to
vehicle control for cells isolated from the same animal.
Normalization was performed to minimize variations in
basal wave activity seen between cells isolated from differ-
ent animals. CX-4945 and sunitinib both increased the fre-
quency of Ca2+ waves by 2 ± 0.3- and 2.2 ± 0.2-fold
respectively. Consistent with their lack of effect on SOICR
occurrence in HEK293 cells, neither ponatinib nor
nilotinib significantly altered the occurrence of Ca2+ waves
(0.8 ± 0.3 and 0.9 ± 0.2 of vehicle respectively).
VK-II-86 can reverse the effect of class I kinase
inhibitors by reducing Ca2+ wave generation in
isolated rat cardiomyocytes
We have previously shown that a non-β-blocking carve-
dilol analogue, VK-II-86, is able to effectively suppress
SOICR through a specific effect on RyR2 (Zhou et al.,
2011). Therefore, we explored whether this compound
could protect against the effect of class I kinase inhibitors
on Ca2+ wave generation. Ventricular myocytes were pre-
inbubated with 1 μM VK-II-86 or vehicle control for
30 min before being exposed to the same protocol as de-
scribed above (1 μM VK-II-86 was present throughout the
assay). Figure 7B shows that VK-II-86 is able to markedly
reduce the frequency of Ca2+ waves in myocytes treated
with CX-4945 (reduced to 0.5 ± 0.1 of cells treated with
CX-4945 alone) and sunitinib (reduced to 0.4 ± 0.1 of cells
treated with sunitinib alone).
Discussion
This study examined the effect of class I and II kinase in-
hibitors on RyR2 function. It found that class I kinase in-
hibitors can increase the propensity for spontaneous Ca2+
release (SOICR) due to a drug-induced increase in channel
function (Po) in the presence of ATP. Although not
observed at the cell level, class II kinase inhibitors tended
to have an inhibitory effect on RyR2 through a decrease
in Po. These data may explain the pro-arrhythmogenic na-
ture of several class I kinase inhibitors and perhaps the
cardiotoxicity of class II compounds. We also show that
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the use of a known anti-SOICR agent, designed to reverse the ef-
fect of RyR2 mutations on channel function, is able to protect
against class I kinase inhibitor-induced increases in SOICR.
Class I kinase inhibitors increase RyR2 single
channel activity and propensity for SOICR
A key finding of this study is that class I kinase inhibitors can
alter the function of RyR2. In particular, class I kinase inhibi-
tors reduce the FSOICR resulting in a dramatic increase in the
propensity for SOICR. It is well established that a reduction
in the threshold for SOICR, combined with an increase in
SR load, enhances the propensity for SOICR which is com-
monly linked to arrhythmias (Jones et al., 2008; Chen et al.,
2014; Jones et al., 2017). We have found this to be a common
mechanism contributing to how mutations within RyR2, ox-
idation, doxorubicin andmethylxanthine derivatives such as
aminophylline and theophylline all lead to arrhythmia
(Jones et al., 2008; Kong et al., 2008; Hanna et al., 2014;
Waddell et al., 2016). Although class I kinase inhibitors
appear to have a strong agonist effect at the cell level, at the
single channel, the effect is less clear cut. Of the two class I
drugs examined, CX-4945 increased the Po of RyR2 directly,
whereas sunitinib required ATP to become a RyR2 agonist.
Indeed, in the absence of physiological ATP, 1 μM sunitinib
appears to inhibit RyR2 channels. How the presence of ATP
converts sunitinib from an inhibitor to agonist is unclear. As
our single channel data were recorded at a single [Ca2+], it
could be argued that the effect of low concentrations of
sunitinib in the absence of ATP is Ca2+ dependent. Indeed,
it is likely that both CX-4945 and sunitinib work synergisti-
cally with Ca2+, a mechanism shared by other regulators of
RyR2. However, the finding that sunitinib increases SOICR
across all of the [Ca2+]o examined in HEK293 cells suggests
that the inhibitory effect observed in the absence of ATP is
very unlikely to be due to the [Ca2+] used in the single
channel recordings.
Although our data show a strong agonist effect of class I
kinase inhibitors, the molecular mechanism by which either
class I kinase inhibitor increases the activity of RyR2 in the
presence of ATP remains unknown. The interaction of ATP
and other regulators of RyR2 is complex with some, such as
Ca2+, acting synergistically (Yang and Steele, 2000; Lindsay
et al., 2018) and others in opposition (Dulhunty et al.,
2005). Indeed, the precise molecular/structural mechanism
by which ATP and other extensively studied regulators of
RyR2 function, such as caffeine and catecholaminergic poly-
morphic tachycardia causative mutations, also remains
poorly defined. We have previously speculated that they all
act to induce changes in the local structure of RyR2 which
are translated to the channel pore through long-range alloste-
ric interactions (Jones et al., 2017). This mechanism may also
underlie the effects observed in this study. Future studies
utilizing the increasingly detailed structures of RyR may
finally allow these outstanding questions to be addressed.
Class II kinase inhibitors decrease RyR2 single
channel activity
In stark contrast to the effect of class I kinase inhibitors, class
II kinase inhibitors appear to reduce RyR2 function, at least at
the single channel level. Channels treated with either
ponatinib or nilotinib show amarked decrease in Po. Interest-
ingly, the striking inhibitory effect at the single channel level
does not appear to translate to a functional effect at the cell
level as neither compound resulted in a significantly reduced
Figure 7
Class I kinase inhibitors increase Ca2+ wave generation in rat
cardiomyocytes which can be prevented by VK-II-86. Freshly isolated
rat ventricular myocytes were loaded with fluo-4 in KRH buffer.
(A) Cells were superfused with KRH containing 1mMCa2+ and paced
at 0.5 Hz. Cells were treated with vehicle or 10 μM of CX-4945,
ponatinib or nilotinib or 1 μM sunitinib for 10 min before pacing
was stopped for 2 min. The number of spontaneous Ca2+ waves oc-
curring during the 2 min was recorded. At the end of each experi-
ment, cells were perfused with 20 mM caffeine to confirm cell
viability. Data shown are the Ca2+ wave frequency (mean ± SEM)
normalized to vehicle-treated cells from the same animal (10 μM
CX-4945 n = 7; 1 μM sunitinib n = 5; 10 μM ponatinib n = 7;
10 μM nilotinib n = 8, different animals); *P < 0.05 versus vehicle.
(B) As with panel (A) except cells were pre-incubated with 1 μM
VK-II-86 or vehicle control (DMSO) for 30 min prior to imaging. Data
shown are the Ca2+ wave frequency (mean ± SEM) normalized to
non-VK-II-86-treated cells (vehicle control) from the same animal
(n = 5 different animals); *P < 0.05 versus vehicle.
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propensity for SOICR in HEK293 cells or ventricular
myocytes. Combined, these data suggest that class II kinase
inhibitors may reduce single RyR2 channel function but not
sufficiently to alter the activity of the channel in situ. Why
this is the case remains to be determined. As we did not
perform single channel recordings of class II kinase inhibitors
in the presence of ATP, it is possible that this may explain the
seemingly contradictory findings. However, as neither class II
kinase inhibitor had an effect at the more physiologically
relevant cell level, we did not explore this further.
Anti-SOICR agents as a means of reversing the
pro-SOICR effect of class I kinase inhibitors
In this study, we found that both CX-4945 and sunitinib are
potent promotors of SOICR at or near the concentrations
used in animal studies or clinically. In our HEK293 cell assays,
we found that the EC50 to trigger SOICR for CX-4945 and su-
nitinib were 2.3 and 0.8 μM respectively. CX-4945 human
trial data are not yet available, but in animal studies, the effec-
tive dose of CX-4945 results in a peak plasma concentration
(Cmax) of 15 μM (Siddiqui-Jain et al., 2010). The Cmax for suni-
tinib in patients taking a typical oral dose of 50 mg·day1 is
28 ng·mL1 and increases threefold to fourfold over 10 days
(equivalent of ~0.3 μM) (Kim et al., 2009). This indicates that
SOICR is triggered by both drugs at clinically relevant con-
centrations. As the occurrence of SOICR is strongly linked to
arrhythmias and cardiomyopathies, this suggests that some
of the cardiotoxic effects of these drugs may be through this
mechanism. The most common electrical disruption ob-
served with both type I and II kinase inhibitors is a prolonged
QT interval. Recently, mutations within RyR2 have also been
linked to long QT syndrome (Valdivia et al., 2016; Fukuyama
et al., 2017) suggesting that RyR2 dysfunction is, at least in
part, associated with this disease. Characterization of one of
the mutations found that it resulted in a gain-of-function
(Valdivia et al., 2016) which is similar to the effect of class I ki-
nase inhibitors reported here.
Given the clinical relevance of SOICR, there have been
multiple studies offering mechanisms to prevent SOICR as a
means of treating arrhythmia. We have previously shown
that the β-blocker carvedilol and its non-β-blocking deriva-
tive VK-II-86 are able to supress SOICR in HEK293 cells and
myocytes and prevent arrhythmias in mice (Zhou et al.,
2011). Here, we found that consistent with other models of
SOICR, VK-II-86 is able to suppress class I kinase inhibitor-
mediated SOICR events. This suggests not only that carve-
dilol, VK-II-86 or derivatives may be future treatments for
some of the cardiotoxicity of class I kinase inhibitors but also
that these compounds are effective at preventing spontane-
ous Ca2+ release triggered by a multitude of mechanisms.
In summary, we demonstrate that class I kinase inhibi-
tors increase the activity of RyR2 channels (Po) which
causes a decrease in the FSOICR, ultimately increasing the
propensity for SOICR. This may offer a novel insight into
the cardiotoxic effects of these compounds. Excitingly, our
data also suggest that the deleterious effects of these com-
pounds may be reversed using agents known to display
anti-SOICR properties some of which, such as carvedilol,
are already in clinical use.
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Figure S1 EC50 for RyR2 activation by class I kinase inhibi-
tors. HEK293 cells stably expressing RyR2 were loaded with
fluo-4 in KRH buffer. Cells were superfused with KRH contain-
ing 1 mM Ca2+ with various concentrations of either CX-
4945 or sunitinib. The percentage of cells experiencing
SOICR at each drug concentration was normalised the maxi-
mum number of cells experiencing SOICR (at the highest
drug concentration). The EC50 was calculated using the stan-
dard EC50 function in GraphPad Prism 7. For CX-4945;
N = 25 (vehicle), 6 (1 μM), 5 (3 μM), 5 (5 μM), 8 (10 μM), 15
(20 μM) and 18 (30 μM). For sunitinib; N = 17 (vehicle), 6
(0.3 μM), 9 (0.5 μM), 5 (1 μM), 5 (3 μM) and 6 (5 μM).
Figure S2 Class I or II kinase inhibitors do not alter the phos-
phorylation of RyR2 at S2808 or S2814. HEK293 cells express-
ing RyR2 were incubated with 10 μM CX-4945, ponatinib,
nilotinib or 1 μM sunitinib. A. Western blots were performed
using antibodies to total RyR2, S2808 or S2814. B and C. The
labelling of S2808 or S2814 was compared to total RyR2 in
cells treated with each drug and normalised to the ratio in
cells treated with vehicle control. n = 5 independent batches
of HEK293 cells and significance was examined using a
Kruskal-Wallis (Dunn’s post-hoc) test.
Figure S3 Open and closed times for RyR2 channels treated
with class I and II kinase inhibitors. The mean(±SEM) open
(To) and closed (Tc) times (ms) of single RyR2 channels re-
corded over a 30 second period in the presence or absence
of class I and II kinase inhibitors. Currents for each channel
were recorded at ±40 mV and combined for each channel.
For CX-4945, n = 6; sunitinib, n = 6; ponatinib, n = 5;
nilotinib, n = 5, individual channels for each drug. The effect
of each drug on To and Tc was determined using a paired Stu-
dent’s t = test.
Figure S4 Effect of ATP and class I kinase inhibitors on To
and Tc. The open (To) and closed (Tc) times (ms) of single
RyR2 channels recorded over a 30 second period in the pres-
ence of absence of ATP and class I kinase inhibitors. For CX-
4945, n = 8; sunitinib, n = 6. * vs. control; # vs. ATP. The effect
of each drug on To and Tc was determined using a paired
ANOVA with Tukey post-hoc test.
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